JP3644704B2 - Immunoassay - Google Patents

Immunoassay Download PDF

Info

Publication number
JP3644704B2
JP3644704B2 JP24270494A JP24270494A JP3644704B2 JP 3644704 B2 JP3644704 B2 JP 3644704B2 JP 24270494 A JP24270494 A JP 24270494A JP 24270494 A JP24270494 A JP 24270494A JP 3644704 B2 JP3644704 B2 JP 3644704B2
Authority
JP
Japan
Prior art keywords
antigen
antibody
sodium chloride
reaction
measurement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP24270494A
Other languages
Japanese (ja)
Other versions
JPH08105897A (en
Inventor
良子 河野
勝己 吉川
美枝 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sekisui Chemical Co Ltd
Original Assignee
Sekisui Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Chemical Co Ltd filed Critical Sekisui Chemical Co Ltd
Priority to JP24270494A priority Critical patent/JP3644704B2/en
Publication of JPH08105897A publication Critical patent/JPH08105897A/en
Application granted granted Critical
Publication of JP3644704B2 publication Critical patent/JP3644704B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【0001】
【産業上の利用分野】
本発明は、ラテックスからなる不溶性担体を使用し、これに担持した梅毒トレポネーマ抗原と検体中の抗梅毒トレポネーマ抗体との抗原抗体反応に基づいて同抗体を測定する免疫測定法に関し、より詳細には、検出感度が高くしかも非特異反応が少ない免疫測定法に関する。
【0002】
【従来の技術】
抗梅毒トレポネーマ抗体の測定方法の一つとして、梅毒トレポネーマ抗原を不溶性担体に担持させ、同抗原と検体中の抗梅毒トレポネーマ抗体との抗原抗体反応により生じた不溶性担体の凝集の度合を測定することにより該抗体を測定する免疫測定法がある。このような測定方法としては、赤血球凝集反応法、ラテックス凝集法が知られている。
【0003】
この凝集の程度を検出する方法としては、凝集の有無を肉眼で判定する方法と、反応液に光を照射して散乱光あるいは透過光を測定する方法がある。肉眼で判定する方法は定性法あるいは半定量法として用いられている。
【0004】
これらの凝集反応の測定において、目的物質以外の共存物質間の反応による、いわゆる非特異凝集が生じることがある。この問題を防止するために、ウシ血清アルブミン(BSA)、ウマ血清アルブミンなどの免疫学的に不活性なアルブミン類を反応系に添加する方法が提案されている(特開昭58−144748、特開平3−94161)。
【0005】
また、上記凝集反応の測定において、測定感度の向上あるいは抗原抗体反応の促進を目的として、ポリエチレングリコール(以下PEGと略す)などの水溶性高分子化合物を反応系に添加する方法が提案されている(特開昭58−47256、特開平2−257063)。
【0006】
【発明が解決しようとする課題】
しかしながら、上記のようなアルブミン添加によっても、非特異凝集を完全に阻止することは不可能であり、非特異凝集の発生しない梅毒診断薬の開発が望まれていた。
【0007】
また、PEGなどの水溶性高分子化合物は、ロット間で物性的な差違が大きいため、再精製が必要であるという問題点を有しており、汎用性が高く、しかも管理しやすい添加剤が求められている。
【0008】
本発明は、上記の問題を解決するものであり、その目的とするところは、非特異反応が少なく、かつ検出感度が高い抗梅毒トレポネーマ抗体を検出する免疫測定法を提供することにある。
【0009】
【課題を解決するための手段】
本発明は上記目的を達成すべく工夫されたものであり、梅毒トレポネーマ抗原をラテックスからなる不溶性担体に担持させ、同抗原と抗梅毒トレポネーマ抗体との抗原抗体反応により生じた不溶性担体の凝集の度合を測定することにより該抗体を測定する免疫測定法において、該抗原抗体反応の測定系に塩化ナトリウムを0.97〜2.4%(w/v)存在させることを特徴とする免疫測定法である。
【0010】
本発明で用いられる不溶性担体としては、ラテックス懸濁液が用いられる。ラテックスとしては、例えばポリスチレン、スチレン−スチレンスルホン酸塩重合体、アクリロニトリル−ブタジエン−スチレン共重合体、塩化ビニル−アクリル酸エステル共重合体、ポリ酢酸ビニルアクリレートなどがある。用いるラテックスの平均粒径は、測定方法、測定機器によって0.05〜1.0μmの範囲で適宜選択される。
【0011】
本発明により抗梅毒トレポネーマ抗体を測定する場合の測定系には、ラテックス凝集反応が利用される。試薬の調製は、まず、公知の方法により、不溶性担体に梅毒トレポネーマ抗原を物理的あるいは化学的結合により感作させる。用いる抗原は菌体破砕物でも精製物でもよい。また、遺伝子組み換えの技術により人工的に合成されたものを1種あるいはそれ以上組み合わせたものでもよい。
【0012】
つぎに、測定系について説明する。
【0013】
本発明では、梅毒トレポネーマ抗原を担持したラテックス試薬に予め塩化ナトリウムを添加しておく。また、塩化ナトリウムを含まないラテックス試薬を使用することも可能で、この場合には抗原抗体反応時に塩化ナトリウムが該反応系に存在するようにすればよい。例えば、検体に予め塩化ナトリウムを添加しておく方法や、使用する緩衝液にこれを添加しておく方法などがあり、特に限定されない。言い換えれば、本発明の測定試薬は、例えば、梅毒トレポネーマ抗原を担持した不溶性担体と塩化ナトリウムとを含む1液系の試薬;梅毒トレポネーマ抗原を担持した不溶性担体を含む第1試薬と、塩化ナトリウムを含む緩衝液からなる第2試薬とで構成された2液系の試薬;など種々の形態でありうる。
【0014】
このような試薬を用いて凝集反応を行い、生じた凝集の程度を光学的に観察もしくは目視観察することにより抗梅毒トレポネーマ抗体が測定される。具体的には、不溶性担体の凝集の程度を光学的に検出する方法においては、測定は散乱光強度、吸光度または透過光強度を測定する光学機器で行う。測定の波長は300〜2400nmの範囲である。測定方法は公知の方法に従い、用いる不溶性担体の粒子の大きさあるいは濃度の選択、反応時間の設定により、散乱光強度、吸収光度または透過光強度の増加もしくは減少を測定する。また、これらの方法を併用することも可能である。
【0015】
不溶性担体の凝集の程度を肉眼で判定する試薬においては、通常、試料と感作不溶性担体を含む溶液を判定板上で混合し、混合液を揺り動かした後、凝集の有無を判定する。凝集判定には、単に肉眼判定以外に、凝集状態をビデオカメラで撮影し、画像処理を施すことによって判定を行うことも可能である。
【0016】
つぎに、測定条件について説明する。
【0017】
本発明の免疫測定法において、抗原抗体反応の反応系に存在する塩化ナトリウムの濃度は共存するタンパク、糖類、水溶性高分子などの増感剤の濃度によって適宜選ばれる。塩化ナトリウムは、該反応系に0.97〜2.4%(w/v)の割合で含有されるように調整される。塩化ナトリウムの濃度が0.97%(w/v)未満であると非特異凝集抑制の効果が認められない。また、この濃度が2.4%(w/v)を越えると抗原抗体反応が抑制され、検出感度が低下する。
【0018】
本発明において抗原抗体反応の条件は通常の場合と同様であり、反応媒体としては、リン酸緩衝液、グリシン緩衝液、トリス緩衝液などが使用される。反応系のpHは4.5〜10.0が好ましく、6〜8が特に好ましい。反応温度は0〜50℃が好ましく、4〜40℃の範囲が特に好ましい。反応時間は適宜決められる。
【0019】
【実施例】
以下に、本発明の実施例を述べ、その効果を具体的に説明する。
【0020】
比較例4
(1)梅毒トレポネーマ抗原感作ラテックス液の調製
100mMリン酸緩衝液(pH7.4)に150μg/mlの蛋白濃度で溶解した梅毒トレポネーマ抗原液400μlを平均粒径0.400μmのポリスチレンラテックス(固形分10%(w/v)、積水化学社製)100μlに添加し、4℃にて1時間攪拌した。次いで、BSAを1%(w/v)含有する100mMリン酸緩衝液(pH7.4)2mlを添加し、1.5時間攪拌した。この液を、10℃にて30分間、18,000rpmで遠心分離した。得られた沈殿物にBSAを0.25%(w/v)含有する100mMリン酸緩衝液(pH7.4)5mlを添加し、ラテックスを懸濁させ、梅毒トレポネーマ抗原感作ラテックスを調製した。
【0021】
(2)検体希釈液の調製
BSAを0.25%(w/v)、pGEMA(グリコシルエチルメタクリレートのホモポリマー、平均分子量114万、日本精化社製)を1%(w/v)含有する100mMリン酸緩衝液(pH7.4)に塩化ナトリウムをその濃度が150mMになるよう溶解した。
【0022】
(3)抗梅毒トレポネーマ抗体測定試薬
抗梅毒トレポネーマ抗体測定試薬は、上記(1)項の梅毒トレポネーマ抗原感作ラテックスからなる第1試薬と、上記(2)の緩衝液からなる第2試薬とから構成される2液系の試薬である。
【0023】
(4)標準物質
抗梅毒トレポネーマ抗体を0、17、67、475T.U.(タイターユニット)含むヒト血清を標準抗梅毒トレポネーマ抗体液として使用した。
【0024】
(5)自動分析装置による抗梅毒トレポネーマ抗体価の測定
以下に、生化学自動分析装置「日立7050形」(日立制作所社製)により、検体中の抗梅毒トレポネーマ抗体を測定する方法を示す。
【0025】
測定モード ;Original Abs
パラメーター;検体量 20μl
ラテックス試薬(第1試薬)量 50μl
検体希釈液(第2試薬)量 350μl
測定波長 ;570nm
測定時間 ;検体分注後、直ちに検体希釈液が添加・混合され、その後、ラテックス試薬が添加・混合される。ラテックス試薬の添加後80秒から320秒まで吸光度変化量を求め、これを反応量とした。
【0026】
塩化ナトリウムの濃度は該反応系に0.73%(w/v)である。
【0027】
実施例2
比較例4の(2)検体希釈液の調製において、BSAを0.25%(w/v)、pGEMAを1%(w/v)含有する100mMリン酸緩衝液(pH7.4)に塩化ナトリウムをその濃度が200mMになるよう溶解し、得られた検体希釈液を使用して(5)測定を行った以外は比較例4と同様の操作を行った。塩化ナトリウムの濃度は該反応系に0.97%(w/v)である。
【0028】
実施例3
比較例4の(2)検体希釈液の調製において、BSAを0.25%(w/v)、pGEMAを1%(w/v)含有する100mMリン酸緩衝液(pH7.4)に塩化ナトリウムをその濃度が500mMになるよう溶解し、得られた検体希釈液を使用して(5)測定を行った以外は比較例4と同様の操作を行った。塩化ナトリウムの濃度は該反応系に2.4%(w/v)である。
【0029】
比較例1
比較例4の(2)検体希釈液の調製において、BSAを0.25%(w/v)、pGEMAを1%(w/v)含有する100mMリン酸緩衝液(pH7.4)に塩化ナトリウムを添加せず、同緩衝液をそのまま検体希釈液として使用して(5)測定を行った以外は比較例4と同様の操作を行った。
【0030】
比較例2
比較例4の(2)検体希釈液の調製において、BSAを0.25%(w/v)、pGEMAを1%(w/v)含有する100mMリン酸緩衝液(pH7.4)に塩化ナトリウムをその濃度が2mMになるよう溶解し、得られた検体希釈液を使用して(5)測定を行った以外は比較例4と同様の操作を行った。塩化ナトリウムの濃度は該反応系に0.01%(w/v)である。
【0031】
比較例3
比較例4の(2)検体希釈液の調製において、BSAを0.25%(w/v)、pGEMAを1%(w/v)含有する100mMリン酸緩衝液(pH7.4)に塩化ナトリウムをその濃度が1500mMになるよう溶解し、得られた検体希釈液を使用して(5)測定を行った以外は比較例4と同様の操作を行った。塩化ナトリウムの濃度は該反応系に7.3%(w/v)である。
【0032】
結果
実施例2〜3および比較例1〜4で得られた、検体の吸光度変化量を表1にまとめた。いずれもn=2の平均値を示す。
【0033】
【表1】

Figure 0003644704
【0034】
上記のように、塩化ナトリウムを所要量添加した系(実施例2〜3)では、その濃度が増加するに連れて感度が若干低下したが、梅毒陰性検体No.1〜3について全て非特異反応を抑制することができた。一方、塩化ナトリウムを添加しない系(比較例1)、および塩化ナトリウムを0.01%(w/v)添加した系(比較例2)では、梅毒陰性検体No. 1〜3の非特異反応を抑制することができなかった。また、塩化ナトリウムを7.3%(w/v)添加した系(比較例3)では、梅毒陰性検体No.1〜3の非特異反応は抑制できたが、梅毒陽性抗体での反応性も大きく低下し、必要な測定範囲が得られなかった。
【0035】
【発明の効果】
本発明の以上の通り構成されているので、非特異反応が少なく、かつ検出感度が高い抗梅毒トレポネーマ抗体を検出する免疫測定法を提供することができる。[0001]
[Industrial application fields]
The present invention relates to an immunoassay method for measuring an antibody based on an antigen-antibody reaction between a syphilis treponema antigen carried on a latex and an anti-syphilis treponema antibody in a sample using an insoluble carrier made of latex. The present invention relates to an immunoassay with high detection sensitivity and low non-specific reaction.
[0002]
[Prior art]
One method of measuring anti-syphilis treponema antibody is to support syphilis treponema antigen on an insoluble carrier and measure the degree of aggregation of the insoluble carrier caused by antigen-antibody reaction between the antigen and anti-syphilis treponema antibody in the sample. There is an immunoassay method for measuring the antibody. As such a measuring method, the hemagglutination reaction method and the latex agglutination method are known.
[0003]
As a method for detecting the degree of aggregation, there are a method for determining the presence or absence of aggregation with the naked eye, and a method for measuring scattered light or transmitted light by irradiating light to a reaction solution. The method of judging with the naked eye is used as a qualitative method or a semi-quantitative method.
[0004]
In the measurement of these aggregation reactions, so-called non-specific aggregation may occur due to a reaction between coexisting substances other than the target substance. In order to prevent this problem, a method has been proposed in which immunologically inactive albumins such as bovine serum albumin (BSA) and horse serum albumin are added to the reaction system (Japanese Patent Laid-Open No. 58-144748). Kaihei 3-94161).
[0005]
In addition, in the measurement of the agglutination reaction, a method of adding a water-soluble polymer compound such as polyethylene glycol (hereinafter abbreviated as PEG) to the reaction system has been proposed for the purpose of improving measurement sensitivity or promoting antigen-antibody reaction. (JP 58-47256, JP 2-257063).
[0006]
[Problems to be solved by the invention]
However, even when albumin is added as described above, it is impossible to completely prevent non-specific aggregation, and development of a syphilis diagnostic agent that does not cause non-specific aggregation has been desired.
[0007]
In addition, water-soluble polymer compounds such as PEG have a problem that they need to be re-purified because of the large physical differences between lots, and are highly versatile and easy to manage additives. It has been demanded.
[0008]
The present invention solves the above-mentioned problems, and an object of the present invention is to provide an immunoassay method for detecting an anti-syphilis treponema antibody having a low non-specific reaction and high detection sensitivity.
[0009]
[Means for Solving the Problems]
The present invention has been devised to achieve the above-mentioned object, and the degree of aggregation of an insoluble carrier produced by an antigen-antibody reaction between the antigen and an anti-syphilis treponema antibody supported on an insoluble carrier made of latex. In an immunoassay method for measuring the antibody by measuring the amount of sodium chloride in the antigen-antibody reaction measurement system, 0.97 to 2.4% (w / v) is present. is there.
[0010]
A latex suspension is used as the insoluble carrier used in the present invention. Examples of the latex include polystyrene, styrene-styrene sulfonate polymer, acrylonitrile-butadiene-styrene copolymer, vinyl chloride-acrylic acid ester copolymer, and polyvinyl acetate acrylate. The average particle size of the latex to be used is appropriately selected in the range of 0.05 to 1.0 μm depending on the measurement method and the measurement equipment.
[0011]
The latex agglutination reaction is used in the measurement system for measuring the anti-syphilis treponema antibody according to the present invention. In preparing the reagent, first, a syphilis treponema antigen is sensitized to the insoluble carrier by physical or chemical binding by a known method. The antigen to be used may be a crushed cell or a purified product. Moreover, what was synthesize | combined artificially by the technique of gene recombination and what combined 1 type or more may be used.
[0012]
Next, the measurement system will be described.
[0013]
In the present invention, sodium chloride is added in advance to the latex reagent carrying the syphilis treponema antigen. It is also possible to use a latex reagent that does not contain sodium chloride. In this case, sodium chloride may be present in the reaction system during the antigen-antibody reaction. For example, there are a method of adding sodium chloride to a specimen in advance and a method of adding sodium chloride to a buffer to be used, and the method is not particularly limited. In other words, the measurement reagent of the present invention includes, for example, a one-component reagent containing an insoluble carrier carrying syphilis treponema antigen and sodium chloride; a first reagent containing an insoluble carrier carrying syphilis treponema antigen; and sodium chloride. It may be in various forms such as a two-component reagent composed of a second reagent comprising a buffer solution.
[0014]
An anti-syphilis treponema antibody is measured by conducting an agglutination reaction using such a reagent and optically or visually observing the degree of aggregation that has occurred. Specifically, in the method of optically detecting the degree of aggregation of an insoluble carrier, the measurement is performed with an optical instrument that measures scattered light intensity, absorbance, or transmitted light intensity. The measurement wavelength is in the range of 300-2400 nm. According to a known method, the increase or decrease in scattered light intensity, absorbed light intensity, or transmitted light intensity is measured by selecting the size or concentration of particles of the insoluble carrier to be used and setting the reaction time. These methods can be used in combination.
[0015]
In the reagent for judging the degree of aggregation of the insoluble carrier with the naked eye, the sample and the solution containing the sensitized insoluble carrier are usually mixed on the judgment plate, and the mixed solution is shaken, and then the presence or absence of aggregation is judged. In addition to the naked eye determination, the agglutination determination can be performed by photographing the aggregation state with a video camera and performing image processing.
[0016]
Next, measurement conditions will be described.
[0017]
In the immunoassay method of the present invention, the concentration of sodium chloride present in the reaction system of the antigen-antibody reaction is appropriately selected depending on the concentration of sensitizers such as coexisting proteins, saccharides and water-soluble polymers. Sodium chloride is adjusted to be contained in the reaction system at a ratio of 0.97 to 2.4% (w / v) . When the concentration of sodium chloride is less than 0.97% (w / v) , the effect of suppressing nonspecific aggregation is not observed. On the other hand, when this concentration exceeds 2.4% (w / v), the antigen-antibody reaction is suppressed and the detection sensitivity is lowered.
[0018]
In the present invention, the conditions for the antigen-antibody reaction are the same as in the usual case, and a phosphate buffer, glycine buffer, Tris buffer or the like is used as the reaction medium. The pH of the reaction system is preferably from 4.5 to 10.0, particularly preferably from 6 to 8. The reaction temperature is preferably 0 to 50 ° C, particularly preferably 4 to 40 ° C. The reaction time is appropriately determined.
[0019]
【Example】
Examples of the present invention will be described below, and the effects will be specifically described.
[0020]
Comparative Example 4
(1) Preparation of syphilis treponema antigen-sensitized latex solution 400 μl of syphilis treponema antigen solution dissolved at a protein concentration of 150 μg / ml in 100 mM phosphate buffer (pH 7.4) with a latex latex having an average particle size of 0.400 μm (solid content) 10% (w / v), manufactured by Sekisui Chemical Co., Ltd.) and stirred at 4 ° C. for 1 hour. Subsequently, 2 ml of 100 mM phosphate buffer (pH 7.4) containing 1% (w / v) BSA was added and stirred for 1.5 hours. This solution was centrifuged at 18,000 rpm for 30 minutes at 10 ° C. To the resulting precipitate, 5 ml of 100 mM phosphate buffer (pH 7.4) containing 0.25% (w / v) BSA was added, and the latex was suspended to prepare a syphilis treponema antigen-sensitized latex.
[0021]
(2) Preparation of specimen dilution solution 0.25% (w / v) of BSA and 1% (w / v) of pGEMA (a homopolymer of glycosylethyl methacrylate, average molecular weight of 1.14 million, manufactured by Nippon Seika Co., Ltd.) Sodium chloride was dissolved in 100 mM phosphate buffer (pH 7.4) to a concentration of 150 mM.
[0022]
(3) Anti-syphilis treponema antibody measurement reagent The anti-syphilis treponema antibody measurement reagent comprises the first reagent comprising the syphilis treponema antigen-sensitized latex described in (1) above and the second reagent comprising the buffer solution described in (2) above. It is a configured two-component reagent.
[0023]
(4) 0, 17, 67, 475T. U. Human serum containing (titer unit) was used as a standard anti-syphilis treponema antibody solution.
[0024]
(5) Measurement of anti-syphilis treponema antibody titer by automatic analyzer The following is a method for measuring anti-syphilis treponema antibody in a specimen using a biochemical automatic analyzer “Hitachi 7050” (manufactured by Hitachi, Ltd.).
[0025]
Measurement mode: Original Abs
Parameter; Sample volume 20μl
Latex reagent (first reagent) volume 50μl
Sample dilution (second reagent) volume 350 μl
Measurement wavelength: 570 nm
Measurement time: Immediately after sample dispensing, the sample diluent is added and mixed, and then the latex reagent is added and mixed. The change in absorbance was determined from 80 seconds to 320 seconds after the addition of the latex reagent, and this was used as the reaction amount.
[0026]
The concentration of sodium chloride is 0.73% (w / v) in the reaction system.
[0027]
Example 2
In the preparation of the sample diluent (2) of Comparative Example 4 , 100 mM phosphate buffer solution (pH 7.4) containing 0.25% (w / v) BSA and 1% (w / v) pGEMA was added with sodium chloride. Was dissolved to a concentration of 200 mM, and the same operation as in Comparative Example 4 was performed, except that (5) measurement was performed using the obtained specimen diluent. The concentration of sodium chloride is 0.97% (w / v) in the reaction system.
[0028]
Example 3
In the preparation of the sample diluent (2) of Comparative Example 4 , 100 mM phosphate buffer solution (pH 7.4) containing 0.25% (w / v) BSA and 1% (w / v) pGEMA was added with sodium chloride. Was dissolved in a concentration of 500 mM, and the same operation as in Comparative Example 4 was performed, except that (5) measurement was performed using the obtained specimen diluent. The concentration of sodium chloride is 2.4% (w / v) in the reaction system.
[0029]
Comparative Example 1
In the preparation of the sample diluent (2) of Comparative Example 4 , 100 mM phosphate buffer solution (pH 7.4) containing 0.25% (w / v) BSA and 1% (w / v) pGEMA was added with sodium chloride. The same operation as in Comparative Example 4 was performed, except that (5) measurement was performed using the same buffer solution as the specimen diluent without adding.
[0030]
Comparative Example 2
In the preparation of the sample diluent (2) of Comparative Example 4 , 100 mM phosphate buffer solution (pH 7.4) containing 0.25% (w / v) BSA and 1% (w / v) pGEMA was added with sodium chloride. Was dissolved to a concentration of 2 mM, and the same operation as in Comparative Example 4 was performed except that (5) measurement was performed using the obtained specimen diluent. The concentration of sodium chloride is 0.01% (w / v) in the reaction system.
[0031]
Comparative Example 3
In the preparation of the sample diluent (2) of Comparative Example 4 , 100 mM phosphate buffer solution (pH 7.4) containing 0.25% (w / v) BSA and 1% (w / v) pGEMA was added with sodium chloride. Was dissolved so that the concentration became 1500 mM, and the same operation as in Comparative Example 4 was performed except that (5) measurement was performed using the obtained specimen diluent. The concentration of sodium chloride is 7.3% (w / v) in the reaction system.
[0032]
result
Table 1 shows the change in absorbance of the specimens obtained in Examples 2-3 and Comparative Examples 1-4 . All show the average value of n = 2.
[0033]
[Table 1]
Figure 0003644704
[0034]
As described above, in the system to which a required amount of sodium chloride was added ( Examples 2 to 3 ), the sensitivity slightly decreased as the concentration increased. All of 1-3 were able to suppress non-specific reactions. On the other hand, the syphilis-negative specimen No. 1 was used in the system not added with sodium chloride (Comparative Example 1) and the system added with 0.01% (w / v) sodium chloride (Comparative Example 2). 1-3 non-specific reactions could not be suppressed. In the system (Comparative Example 3) to which sodium chloride was added at 7.3% (w / v), the syphilis negative specimen No. Although the non-specific reactions 1 to 3 could be suppressed, the reactivity with the syphilis-positive antibody was greatly reduced, and the required measurement range could not be obtained.
[0035]
【The invention's effect】
Since it is comprised as mentioned above of this invention, the immunoassay which detects an anti- syphilis treponema antibody with few nonspecific reactions and high detection sensitivity can be provided.

Claims (1)

梅毒トレポネーマ抗原をラテックスからなる不溶性担体に担持させ、同抗原と抗梅毒トレポネーマ抗体との抗原抗体反応により生じた不溶性担体の凝集の度合を測定することにより該抗体を測定する免疫測定法において、該抗原抗体反応の測定系に塩化ナトリウムを0.97〜2.4%(w/v)存在させることを特徴とする免疫測定法。In an immunoassay method for measuring the antibody by carrying the syphilis treponema antigen on an insoluble carrier made of latex and measuring the degree of aggregation of the insoluble carrier caused by the antigen-antibody reaction between the antigen and the anti-syphilis treponema antibody, An immunoassay method, wherein sodium chloride is present in an antigen-antibody reaction measurement system in an amount of 0.97 to 2.4% (w / v) .
JP24270494A 1994-10-06 1994-10-06 Immunoassay Expired - Lifetime JP3644704B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP24270494A JP3644704B2 (en) 1994-10-06 1994-10-06 Immunoassay

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24270494A JP3644704B2 (en) 1994-10-06 1994-10-06 Immunoassay

Publications (2)

Publication Number Publication Date
JPH08105897A JPH08105897A (en) 1996-04-23
JP3644704B2 true JP3644704B2 (en) 2005-05-11

Family

ID=17093012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP24270494A Expired - Lifetime JP3644704B2 (en) 1994-10-06 1994-10-06 Immunoassay

Country Status (1)

Country Link
JP (1) JP3644704B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006227027A (en) * 2000-12-28 2006-08-31 Shino Test Corp Measuring reagent for measured material
JP5143046B2 (en) * 2009-02-12 2013-02-13 富士フイルム株式会社 Test substance measurement method and kit for carrying out the measurement method

Also Published As

Publication number Publication date
JPH08105897A (en) 1996-04-23

Similar Documents

Publication Publication Date Title
US4060597A (en) Serological reagent and preparation thereof
CA1146852A (en) Reagent for latex agglutination
EP1416277B1 (en) Carrier particle latex for assay reagent and assay reagent
JPS6243138B2 (en)
JPH11337551A (en) Non-specific reaction suppression agent, immunity measuring reagent, and immunity measuring method
JP4629564B2 (en) Anti-Treponema / Paridum antibody measurement reagent
JP3644704B2 (en) Immunoassay
JP3771413B2 (en) Antiphospholipid antibody measuring reagent, method for producing the same, and antiphospholipid antibody measuring method
JP5088471B2 (en) Target substance detection method and reagent for latex agglutination reaction
JP2682697B2 (en) Immunoassay reagents and immunoassays
JP2004325414A (en) Method and kit for measuring immunity
JPH1123573A (en) Immunological measuring method
JP3618797B2 (en) Immunoassay
JP2000046828A (en) Immunoassay reagent and production thereof
JP3048306B2 (en) Fibrin degradation product and / or fibrinogen degradation product measuring reagent and method for quantifying the same
JP2000258419A (en) Immuno-measuring reagent and immuno-measuring method
JPH0650312B2 (en) How to remove non-specific turbidity
JPS6366464A (en) Carrier latex for diagnosing reagent
JPH10221338A (en) Reagent and kit for simultaneous fractional measurement of hemoglobin in feces and transferrin, and screening method of hemorrhagic digestive tract disease
JPH08278308A (en) Immunoassay method
JP3692055B2 (en) Determination method of antigen-antibody reaction
JP3692056B2 (en) Determination method of antigen-antibody reaction
JPH09304389A (en) Immunoassay reagent and immunoassay
JPH07270423A (en) Production of immunologically diagnosing medicine
JPH10311830A (en) Immunoassay reagent and immunoassay

Legal Events

Date Code Title Description
A912 Removal of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20040116

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050201

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080210

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090210

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100210

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100210

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110210

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120210

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130210

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140210

Year of fee payment: 9

EXPY Cancellation because of completion of term